Bridging Bench to Bedside: Challenges in Advancing Remyelination Therapies
Positive Phase 3 Data for Oral OSA Medication AD109, FDA Clears First Blood Test for Alzheimer Disease, DHE Autoinjector Treatment Approved for Migraine
NeurologyLive® Friday 5 — May 23, 2025
From Imaging to Biomarkers: Improving Remyelination Assessment in MS